SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 /PRNewswire/ -- GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, presented preclinical research on its industry-leading Surge™ technology at the 2018 Keystone Symposia on Antibodies as Drugs: Translating Molecules into Treatments. In its research, GigaGen used Surge, a high-throughput single cell droplet microfluidic technology, to rapidly discover high-affinity, fully human antibody drug candidates against 17 immuno-oncology targets — far exceeding what is possible through conventional hybridoma screening.
"Surge is a powerful technology for discovering novel antibodies with high therapeutic potential against cancer, one of the most serious diseases of immune dysregulation," said David Johnson, Ph.D., Chief Executive Officer of GigaGen. "These key research findings have once again validated Surge's ability to interrogate the entire immune system with unprecedented depth and breadth, leading to faster selection of drug targets and assessment of pre-clinical drug efficacy."
Dr. Johnson presented a poster titled "Rapid Discovery of High-Affinity, Human Antibodies Against 17 Immuno-Oncology Targets Using Molecular Genomic Screening Methods."
Key findings include:
- GigaGen's discovery program, powered by Surge, is significantly faster and more comprehensive than conventional hybridoma screening. In approximately two months, the program produced a broad range of sequenced and functionally validated human antibodies from immunized mice.
- GigaGen identified more than 2,300 unique monoclonal antibodies against 17 cancer targets: PD-1, PD-L1, CTLA-4, LAG-3, TIM-3, B7-H3, B7-H4, TIGIT, TLR2, TLR4, CSF1R, VISTA, CD47, OX40, GITR, CD27 and ICOS.
- Several of the potential drug candidates for each target were evaluated as full-length antibodies for binding kinetics and epitope binning using surface plasmon resonance and for function using cell-based reporter assays.
The most promising antibody candidates that resulted from these discovery efforts are now part of GigaGen's extensive portfolio of human antibodies and are undergoing affinity maturation and pre-clinical efficacy studies to further assess their developability.
A copy of the poster is now available on the company's website at www.gigagen.com.
The 2018 Keystone Symposia on Antibodies as Drugs: Translating Molecules into Treatments (#KSantibodies) is a platform for knowledge-sharing from the molecular to the systems level to navigate the newest developments and insights to prevent, treat and cure major human diseases. Held in Whistler, British Columbia, the peer-reviewed conference connect the scientific community and accelerate life science discovery.
GigaGen is a privately-held, preclinical biopharmaceutical company developing novel antibody therapies to treat diseases of immune dysregulation. GigaGen's deep understanding of immune dysregulation is enabled by industry-leading technology that quickly captures the genetic makeup of entire immune repertoires to analyze B cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. GigaGen has a robust internal pipeline consisting of novel antibodies against immuno-oncology targets, in addition to the first recombinant intravenous immunoglobulin (IVIG) for patients with immune deficiency. For more information visit www.GigaGen.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/gigagen-presents-methods-for-rapid-immuno-oncology-antibody-discovery-at-2018-keystone-symposia-on-antibodies-as-drugs-300604995.html
SOURCE GigaGen Inc.